AmeriPath Stock Offering Pulled By Underwriters

Efforts to become first publicly traded pathology management firm stymied by market conditions

CEO SUMMARY: Ameripath planned to go public in March. However, the stock market’s significant decline and further evaluation of the company’s business plan caused Wall Street underwriters to defer issuing the stock. Pathologists are curious as to whether AmeriPath’s “employee” business model influenced decisions about the public stock offering.

UNDERWRITERS on Wall Street decided to delay

Subscriber-Only Content. Please Log In.

You are trying to access subscribers-only content. If you are a subscriber, please log in.

If you are not a subscriber, click here to see subscription offers.

Subscribers will have instant access to the Dark Report library, 1997 - the present, giving you the most convenient, accessible archive available in laboratory business intelligence today!

To read our FREE article previews, go to The Dark Report Insider.

Tags: , , , , , , , , , , , , , , , ,

Enter Your Login Credentials
This setting should only be used on your home or work computer.

×

Send this to friend